12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Belinostat: Phase I/II data

The open-label, European Phase I/II PXD101-CLN-15 trial in 41 patients with AML not suitable for intensive induction therapy showed that belinostat plus idarubicin produced 5 complete remissions (CRs) and 2 partial remissions (PRs) in patients with low/intermediate-risk cytogenetic aberrations (n=25) and no CRs and 2 PRs in high-risk patients (n=16). Patients received...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >